164 related articles for article (PubMed ID: 8883414)
1. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.
Apakama I; Robinson MC; Walter NM; Charlton RG; Royds JA; Fuller CE; Neal DE; Hamdy FC
Br J Cancer; 1996 Oct; 74(8):1258-62. PubMed ID: 8883414
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy.
Cesinaro AM; Migaldi M; Ferrari G; Castagnetti G; Dotti A; De Gaetani C; Ferrari P; Trentini GP
Oncol Res; 2000; 12(1):43-9. PubMed ID: 11061345
[TBL] [Abstract][Full Text] [Related]
3. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
[TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer.
McDonnell TJ; Navone NM; Troncoso P; Pisters LL; Conti C; von Eschenbach AC; Brisbay S; Logothetis CJ
J Urol; 1997 Feb; 157(2):569-74. PubMed ID: 8996359
[TBL] [Abstract][Full Text] [Related]
5. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of potential therapeutic targets in prostate cancer.
Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L
Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903
[TBL] [Abstract][Full Text] [Related]
7. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma.
Byrne RL; Horne CH; Robinson MC; Autzen P; Apakama I; Bishop RI; Neal DE; Hamdy FC
Br J Urol; 1997 Feb; 79(2):190-5. PubMed ID: 9052469
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.
Castilla C; Congregado B; Conde JM; Medina R; Torrubia FJ; Japón MA; Sáez C
Urology; 2010 Oct; 76(4):1017.e1-6. PubMed ID: 20708221
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
[TBL] [Abstract][Full Text] [Related]
10. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells.
Martinez LA; Yang J; Vazquez ES; Rodriguez-Vargas Mdel C; Olive M; Hsieh JT; Logothetis CJ; Navone NM
Carcinogenesis; 2002 Aug; 23(8):1289-96. PubMed ID: 12151346
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis regulating genes in prostate cancer (review).
Johnson MI; Hamdy FC
Oncol Rep; 1998; 5(3):553-7. PubMed ID: 9538152
[TBL] [Abstract][Full Text] [Related]
12. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
[TBL] [Abstract][Full Text] [Related]
14. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy.
Rakozy C; Grignon DJ; Sarkar FH; Sakr WA; Littrup P; Forman J
Mod Pathol; 1998 Sep; 11(9):892-9. PubMed ID: 9758370
[TBL] [Abstract][Full Text] [Related]
16. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
17. p53, Bcl-2 and AgNOR tissue markers: model approach in predicting prostate cancer characteristics.
Munda M; Hajdinjak T; Kavalar R; Stiblar Martincic D
J Int Med Res; 2009; 37(6):1868-76. PubMed ID: 20146885
[TBL] [Abstract][Full Text] [Related]
18. Low apoptotic activity in primary prostate carcinomas without response to hormonal therapy.
Palmberg C; Rantala I; Tammela TL; Helin H; Koivisto PA
Oncol Rep; 2000; 7(5):1141-4. PubMed ID: 10948353
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells.
Mohapatra S; Chu B; Zhao X; Pledger WJ
Cancer Res; 2005 Sep; 65(17):7717-23. PubMed ID: 16140939
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Serafin AM; Akudugu JM; Bohm L
Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
